Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Imatinib and altered bone and mineral metabolism.

Literature DB >> 16903020

Imatinib and altered bone and mineral metabolism.

Heikki Joensuu, Peter Reichardt.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2006 PMID： 16903020

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

Keyword Cloud
Cited

× No keyword cloud information.

8 in total

1. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.

Authors: George D Demetri; Margaret von Mehren; Cristina R Antonescu; Ronald P DeMatteo; Kristen N Ganjoo; Robert G Maki; Peter W T Pisters; Chandrajit P Raut; Richard F Riedel; Scott Schuetze; Hema M Sundar; Jonathan C Trent; Jeffrey D Wayne
Journal: J Natl Compr Canc Netw Date: 2010-04 Impact factor: 11.908

2. Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patients.

Authors: Philipp Ivanyi; Thomas Winkler; Anika Grosshennig; Christoph Reuter; Axel S Merseburger; Arnold Ganser; Viktor Grünwald
Journal: World J Urol Date: 2010-05-05 Impact factor: 4.226

3. Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia.

Authors: Daniela Hoehn; Jorge E Cortes; L Jeffrey Medeiros; Elias J Jabbour; Juliana E Hidalgo; Rashmi Kanagal-Shamanna; Carlos E Bueso-Ramos
Journal: Clin Lymphoma Myeloma Leuk Date: 2016-08

Imatinib and altered bone and mineral metabolism.

1. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.

2. Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patients.

3. Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia.

Review 4. Clinical review: kinase inhibitors: adverse effects related to the endocrine system.

5. Electrolyte disturbances and acute kidney injury induced by imatinib therapy.

6. Tyrosine Kinase Inhibitors Regulate OPG through Inhibition of PDGFRβ.

7. Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

8. A Case of Hypophosphatemia with Increased Urinary Excretion of Phosphorus Associated with Ibrutinib.